PepGen's oligo succeeds in Phase 2; Ionis' and ImmunityBio's stocks sag

Plus news about Coherus Oncology, JW Therapeutics and PsiThera. PepGen’s positive mid-stage results in DM1: PepGen said its oligonucleotide therapy PGN-EDODM1 showed positive early signals in a cohort of Phase 2 patients with myotonic dystrophy ...